Trastuzumab-deruxtecan (Enhertu®) is the first targeted agent to receive approval in advanced or metastatic HER2-overexpressing GC/GEJ cancer patients who retain their Her-2/neu overexpression after progression on 1L trastuzumab-containing treatment. The gene discussed is ERBB2; the disease is gastric cancer.